Outpatient management of inflammatory bowel disease. Let's keep it as simple as possible.
Inflammatory bowel disease is a conglomeration of disorders of unclear etiology and pathogenesis. Confirming the diagnosis of active disease may be difficult but is critical to judicious therapy. Sulfasalazine (Azulfidine) and its newer derivatives mesalamine (Asacol, Rowasa) and olsalazine sodium (Dipentum) are used for treatment of mild disease and maintenance. Corticosteroid therapy controls moderate disease in most patients, but withdrawal may be difficult. Immunosuppression or surgery may be necessary in severe or refractory cases. The risk of cancer as a complication of inflammatory bowel disease is often exaggerated but cannot be ignored.
Butt
J H
JH
Gastrointestinal Section, Harry S Truman Memorial Veterans Affairs Medical Center, Columbia, Missouri.
D015746:Abdominal Pain / Q000209:etiology; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000553:Ambulatory Care; D000636:Aminosalicylic Acids / Q000627:therapeutic use; D001004:Anus Diseases / Q000209:etiology; D003967:Diarrhea / Q000209:etiology; D004415:Dyspepsia / Q000209:etiology; D005334:Fever / Q000209:etiology; D006471:Gastrointestinal Hemorrhage / Q000209:etiology; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications / Q000175:diagnosis / Q000382:microbiology / Q000628:therapy*; D019804:Mesalamine; D009819:Office Visits; D011613:Psychotherapy; D012460:Sulfasalazine / Q000627:therapeutic use; D014376:Tuberculosis / Q000150:complications
D000305:Adrenal Cortex Hormones; D000636:Aminosalicylic Acids; D012460:Sulfasalazine; D019804:Mesalamine